Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen has downgraded Theravance Biopharma (NASDAQ:TBPH) from a "strong-buy" to a "buy" rating. The company's stock opened at $16.02, has a market capitalization of $824.87 million, and a P/E ratio of 7.89. Despite the downgrade, other analysts maintain a "Moderate Buy" consensus with an average target price of $21.33, reflecting mixed views, while an insider recently sold shares.
JPMorgan Chase & Co. Purchases 93,591 Shares of Theravance Biopharma, Inc. $TBPH
JPMorgan Chase & Co. significantly increased its stake in Theravance Biopharma (TBPH) by 78.3%, acquiring an additional 93,591 shares to hold a total of 213,104 shares valued at $3.11 million. This increase in institutional investment comes as analysts have shown more positive sentiment, with several upgrading the stock to "buy" or "strong-buy" and setting an average price target of $21.33. Despite some insider selling, the biopharmaceutical company's stock currently trades around $16.02, with a market capitalization of approximately $824.92 million.
Theravance Biopharma (TBPH) CEO awarded 75,000 Ordinary Shares
Theravance Biopharma's CEO, Rick E. Winningham, was awarded 75,000 Ordinary Shares at no cost, which was recorded as a grant or acquisition. Following this grant, his direct holdings increased to 1,651,094 Ordinary Shares, in addition to indirect holdings through a custodian and a trust. This transaction is considered a compensation-related award rather than a market purchase and reflects no stock sales by the CEO.
Theravance Biopharma (TBPH) SVP awarded 18,750 shares in Form 4 filing
Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, Inc. (TBPH), was awarded 18,750 Ordinary Shares on April 1, 2026, as compensation. These shares were granted at $0.00 per share, increasing her direct holdings to 251,449 Ordinary Shares. This transaction, filed on a Form 4, reflects an increase in her equity-based compensation within the company.
Theravance Biopharma (TBPH) SVP receives 37,500-share equity grant
Brett A. Grimaud, SVP, General Counsel, and Secretary of Theravance Biopharma, Inc. (TBPH), received a grant of 37,500 Ordinary Shares on April 1, 2026, as compensation. These shares were awarded at $0.00 per share, increasing his direct holdings to 371,949 Ordinary Shares. This transaction is characterized as a routine equity grant, not an open-market purchase, and therefore has weaker signaling value regarding market trading decisions.
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro
The Multiple System Atrophy (MSA) market is projected for significant growth, from USD 44 million in 2025 to USD 1,753 million by 2034, driven by advancements in therapies from companies like Alterity Therapeutics, Ionis Pharmaceuticals, and Biohaven Pharmaceuticals. The US currently holds the largest market share, with Germany leading in EU4 and the UK. The report highlights upcoming therapies and stresses the increasing prevalence and awareness of this rare neurodegenerative disorder as key market drivers.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Theravance Biopharma, Inc. (NASDAQ: TBPH) for potential securities law violations. The investigation stems from the company's significant spending on its high-risk CYPRESS trial, which ultimately failed, leading to concerns about false or misleading statements to investors. Shareholders who incurred losses are encouraged to contact the Schall Law Firm to discuss their rights.
TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Theravance Biopharma, Inc. (NASDAQ: TBPH) for potential securities law violations. This investigation stems from allegations that the company made false or misleading statements and failed to disclose critical information to investors, particularly regarding significant operational expenses during its ultimately failed CYPRESS trial. Shareholders who suffered losses are encouraged to contact the law firm to discuss their rights.
TBPH PE Ratio & Valuation, Is TBPH Overvalued
This article analyzes the valuation of Theravance Biopharma Inc (TBPH), concluding that it is currently undervalued. Based on a relative valuation method, TBPH's fair price is estimated to be between $84.42 and $93.72, significantly higher than its current price of $16.02. The analysis also compares TBPH's P/B ratio, FCF yield, and P/S ratio against its historical averages and industry competitors.
How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing
This article analyzes Theravance Biopharma Inc. (TBPH) using quantitative research, highlighting strong sentiment across all horizons for an overweight bias. It provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also details multi-timeframe signal strengths, support, and resistance levels for TBPH.
Tudor Investment Corp ET AL Decreases Stake in Theravance Biopharma, Inc. $TBPH
Tudor Investment Corp ET AL significantly reduced its stake in Theravance Biopharma, Inc. (TBPH) by 74.0% in Q3, selling 145,515 shares and retaining 51,048 shares valued at $745,000. Despite this reduction, analyst sentiment for TBPH is positive, with an average rating of "Moderate Buy" and an average target price of $21.33. Insider selling was also noted, with SVP Rhonda Farnum reducing her holdings by 11.78% in March.
Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement
Theravance Biopharma, Inc. announced a settlement of patent litigation concerning its YUPELRI® (revefenacin) inhalation solution with Mankind Pharma. This agreement grants Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. beginning April 23, 2039. The resolution clarifies the long-term exclusivity of YUPELRI and eliminates legal uncertainties, though it is subject to review by U.S. antitrust authorities.
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission.
Theravance Biopharma Inc. (TBPH) has announced that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC). This agreement is now under review by the Department of Justice and the Federal Trade Commission, marking a critical regulatory evaluation phase for the protocol. The article provides this update without offering investment advice.
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
Theravance Biopharma and its partner Mylan have settled a patent litigation with Mankind Pharma and Lifestar Pharma regarding YUPELRI (revefenacin) inhalation solution. The settlement grants Mankind a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. starting April 23, 2039, securing Theravance’s exclusivity for over a decade. This agreement resolves all pending Hatch-Waxman disputes and provides clarity on YUPELRI's market lifecycle, pending regulatory review.
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission.
Theravance Biopharma Inc. (TBPH) has filed a settlement agreement with the U.S. Securities and Exchange Commission (SEC). This agreement is now under review by the Department of Justice and the Federal Trade Commission, marking a significant step in its regulatory process. The content of the article reflects the author's opinion and is not investment advice.
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen
Wall Street Zen recently upgraded Theravance Biopharma (NASDAQ:TBPH) from a "hold" to a "strong-buy" rating. This upgrade aligns with several other analysts who have either raised ratings or price targets for the company, resulting in a consensus rating of "Moderate Buy" with an average target price of $21.33. The article also details recent insider trading activity and institutional investor holdings, noting that insiders own 6.90% and institutional investors hold 99.10% of the stock.
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49
This article reports a significant decrease in the price target for Theravance Biopharma (TBPH) by 39.48%, lowering it to $16.49. The article is very concise and does not provide further details regarding the reasons for this adjustment.
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49
The price target for Theravance Biopharma (TBPH) has been significantly decreased by 39.48%, bringing it down to $16.49. This adjustment reflects a substantial change in analysts' valuation of the company's stock.
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP
Levi & Korsinsky, LLP announces a securities fraud lawsuit investigation against Theravance Biopharma (TBPH) after the company's stock fell 26% on March 3, 2026. The firm alleges that Theravance Biopharma repeatedly reaffirmed financial guidance, including $75 million in near-term milestones, without adequately disclosing the significant risk that its pivotal CYPRESS Phase 3 trial could fail and materially impact its financial outlook. Shareholders who incurred losses are encouraged to contact Levi & Korsinsky, LLP.
Theravance's Q4 earnings and revenues miss estimates
Theravance reported its Q4 earnings and revenues, both of which fell short of analyst estimates. This news may impact investor sentiment and the company's short-term stock performance.
Weiss Asset Management (TBPH) details 7.46M-share, 14.5% Theravance Biopharma stake
Weiss Asset Management and related entities have filed an amendment to their Schedule 13D, disclosing beneficial ownership of 7,457,060 ordinary shares in Theravance Biopharma, Inc. This represents a 14.5% stake in the company, based on 51,492,924 shares outstanding as of February 28, 2026. The shares are held by BIP (9.0%) and BGO (5.5%), with Weiss Asset Management LP acting as investment manager for both funds, and Andrew M. Weiss holding voting and dispositive power.
Theravance Biopharma 2025 10-K: $107.5M Revenue, $105.9M Net Income
Theravance Biopharma reported total revenues of $107.5 million and net income of $105.9 million for 2025, significantly boosted by non-recurring items like the sale of contingent royalty assets and the TRELEGY sale. The company ended the year with strong operating cash generation and a substantial cash balance, benefiting from strategic realignments including winding down R&D and reducing operating expenses. Sales of YUPELRI also showed significant growth, contributing to improved brand profitability.
Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates
This article reports that Theravance Biopharma (TBPH) missed analyst estimates for both its Q4 earnings and revenues. The company posted a loss per share of $0.66, which was higher than the Zacks Consensus Estimate, and its revenues of $13.68 million also fell short of expectations.
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Zacks Research
Zacks Research has upgraded Theravance Biopharma (NASDAQ:TBPH) to a "Strong-Buy" rating. This upgrade comes after Theravance reported a Q4 beat with EPS of $1.15 and revenue of $45.9M, projecting approximately $400M in cash with no debt by end-Q1 2026 and significant cost savings. However, the company is also undergoing a restructuring, has discontinued a key pipeline candidate, and an SVP recently sold shares, leading to mixed analyst sentiment despite the recent upgrade.
BTIG Research Reaffirms "Buy" Rating for Theravance Biopharma (NASDAQ:TBPH)
BTIG Research has reaffirmed a "Buy" rating for Theravance Biopharma (NASDAQ:TBPH) with a price target of $21.00, suggesting a roughly 49.9% upside. While analyst views are mixed, the consensus remains a "Moderate Buy" with an average price target of $22.60. Theravance Biopharma recently reported a significant beat on its quarterly earnings per share and revenue.
Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base
Theravance Biopharma (TBPH) has transitioned to profitability in FY 2025, with a significant swing from a net loss to a US$105.9 million profit on improved revenue of US$107.5 million. While this supports bullish arguments regarding disciplined spending and potential new products, skeptics highlight the narrow revenue base, modest growth, and projected earnings decline, indicating that the company's long-term stability still needs to be proven beyond its reliance on a few key therapies. Both fair value and analyst price targets suggest the stock may be undervalued compared to peers, despite trading richer than the broader pharmaceuticals industry.
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Beats Estimates By $0.71 EPS
Theravance Biopharma (NASDAQ:TBPH) announced strong quarterly earnings results, reporting $1.15 EPS against an estimated $0.44, and revenues of $45.89 million, surpassing the consensus of $43.09 million. Following the news, the company's stock rose 1.3% to $14.01. Despite a recent insider stock sale, institutional investors hold a significant majority stake, with analysts maintaining a "Moderate Buy" consensus rating and a target price of $22.60.
Theravance Biopharma (TBPH) Profit Swing Reinforces Bullish Narratives Despite Narrow Revenue Base
Theravance Biopharma (TBPH) reported a significant profit swing in FY 2025, moving from a trailing 12-month loss to a profit of US$2.10 Basic EPS and US$105.9 million net income. This shift, driven by products like YUPELRI, supports bullish narratives, but concerns remain regarding the company's narrow revenue base and dependence on a few key products. Despite recent profitability, modest revenue growth and projected earnings decline present mixed signals on its long-term valuation and growth prospects.
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Biopharma (TBPH) reported Q4 earnings of $0.06 per share, significantly missing the Zacks Consensus Estimate of $0.44 per share, despite showing a shift from a loss last year. The company's revenues were $45.89 million, also falling short of expectations. Despite these misses, the stock currently holds a Zacks Rank #2 (Buy) due to favorable estimate revisions ahead of the report.
Theravance Biopharma 2025 Earnings: Q4 Profit $61M, Revenue Misses Estimates - News and Statistics
Theravance Biopharma Inc. reported its Q4 and full-year 2025 financial results. The company posted a Q4 profit of $61 million ($1.15 per share), with adjusted earnings of 6 cents per share, which, along with revenue of $45.9 million, missed analyst expectations. For the entire year, Theravance Biopharma achieved a profit of $105.9 million, or $2.06 per share, on annual revenue of $107.5 million.
Theravance Bio: Q4 Earnings Snapshot
Theravance Biopharma Inc. (TBPH) reported a fourth-quarter profit of $61 million, or $1.15 per share, though adjusted earnings of 6 cents per share missed analyst expectations. The company also reported revenues of $45.9 million, falling short of Wall Street forecasts. For the full year, Theravance Biopharma posted a profit of $105.9 million on $107.5 million in revenue.
Theravance Biopharma reports Q4 2025 net income $61.0M; Q4 revenue $45.9M, cash ~ $400M expected Q1 2026
Theravance Biopharma announced Q4 2025 net income of $61.0 million and revenue of $45.9 million, driven by significant YUPELRI and TRELEGY milestone revenues. The company concluded 2025 with $326.5 million in cash, projecting approximately $400.0 million by the end of Q1 2026 after further milestone receipts. Additionally, Theravance Biopharma is undergoing an organizational restructuring to wind down R&D operations, aiming to reduce operating expenses by about 60% and achieve $60–$70 million in annualized cash flow savings from Q3 2026.
Theravance Bio: Q4 Earnings Snapshot
Theravance Biopharma Inc. (TBPH) reported a fourth-quarter profit of $61 million, or $1.15 per share, but adjusted earnings of 6 cents per share missed Wall Street estimates of 44 cents per share. The company's revenue of $45.9 million also fell short of analysts' expectations of $59.8 million. For the full year, Theravance Biopharma reported a profit of $105.9 million on revenue of $107.5 million.
Theravance Biopharma SVP Farnum sells $433k in shares
Rhonda Farnum, SVP at Theravance Biopharma (NASDAQ:TBPH), sold 31,067 shares worth approximately $433,637 on March 16, 2026. This insider sale follows recent news that the company's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, leading to the winding down of the program, significant expense reductions, and workforce layoffs. Several analysts have downgraded TBPH stock and lowered price targets in response to these developments.
Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 31,067 Shares
Rhonda Farnum, SVP of Theravance Biopharma (NASDAQ:TBPH), sold 31,067 shares for $433,695, reducing her stake by 11.78%. The transaction, dated March 16th, leaves her with 232,699 shares valued at approximately $3.25 million. Following the news, TBPH shares traded down by 0.6% to $13.83, with analysts maintaining a "Moderate Buy" consensus and a price target of $22.60.
Theravance Biopharma (NASDAQ: TBPH) SVP sells 31,067 shares, keeps stake
Rhonda Farnum, SVP, Commercial & Medical Affairs of Theravance Biopharma (NASDAQ: TBPH), sold 31,067 ordinary shares in open-market transactions on March 16, 2026, at prices between $13.755 and $14.01. Following these sales, Farnum directly owns 232,699 ordinary shares of the company. The transaction was executed in accordance with her 10b5-1 plan dated September 3, 2025.
Theravance drops rare disease drug after late-stage trial setback
Theravance Biopharma has decided to discontinue the development of its rare disease drug, ampreloxetine, following a setback in a late-stage trial for symptomatic neurogenic orthostatic hypotension (nOH). The company stated that the trial did not meet its primary endpoint, leading to the decision to stop further investment in the drug. This move will result in a workforce reduction and a redirection of focus to its respiratory therapy, Yupelri.
Insider Sell: Rhonda Farnum Sells Shares of Theravance Biopharma Inc (TBPH)
Rhonda Farnum, Senior Vice President at Theravance Biopharma Ireland Limited, sold 31,067 shares of Theravance Biopharma Inc (TBPH) on March 16, 2026. This transaction brings her total ownership to 232,699 shares. Over the past year, there have been no insider buys but eight insider sells for TBPH, with Farnum selling a total of 100,134 shares. The stock is currently trading at $13.96, indicating it is modestly undervalued with a price-to-GF-Value ratio of 0.72.
Theravance Biopharma to restructure after late-stage ampreloxetine setback
NULL
Once with 360 employees, Theravance Biopharma's latest cuts to whittle workforce to fewer than 50
Theravance Biopharma, once employing 360 people, is drastically reducing its workforce to fewer than 50 following a late-stage clinical trial failure of its drug. The company is now exploring its next steps, including a potential sale, after previously cutting 50% of its workforce and eliminating R&D.
Responsive Playbooks and the TBPH Inflection
This article from Stock Traders Daily discusses Theravance Biopharma Inc. (TBPH), highlighting divergent market sentiment and current price positioning. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis indicating varying strengths across near, mid, and long-term horizons.
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations
Levi & Korsinsky is investigating Theravance Biopharma, Inc. (NASDAQ: TBPH) for potential securities fraud violations after the company's stock fell 26% following the failure of its CYPRESS trial. Previously, company executives had projected achieving significant near-term financial milestones without mentioning the risk of a trial failure. Shareholders who suffered losses are encouraged to contact Levi & Korsinsky to explore potential recovery.
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
Theravance Biopharma (TBPH) has seen a 33.7% decline in the past four weeks, making it appear oversold with an RSI reading of 21.51. This, combined with a 2533.3% increase in consensus EPS estimates for the current year and a Zacks Rank #2 (Buy), suggests a potential trend reversal and an opportunity to buy the dip. Analysts anticipate improved earnings, signaling a strong fundamental rebound for the stock.
Breaking Down Theravance Biopharma: 5 Analysts Share Their Views
Five analysts have recently provided their views on Theravance Biopharma (NASDAQ: TBPH), offering a mix of bullish and indifferent ratings. The average 12-month price target is set at $23.40, a decrease from the previous average, with individual analysts adjusting their ratings and price targets based on market conditions. The company's financials show strong market capitalization, positive revenue growth, and high net margins and returns on equity and assets, while maintaining a sound debt-to-equity ratio.
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure
Theravance Biopharma, Inc. experienced significant stock volatility, dropping 26.33% to an intraday low of $13.08, despite a strong 52.57% increase over the past year. The company reported an 18.51% rise in net sales and has 100% institutional holdings. However, its year-to-date performance has declined by 25.39%, and its P/E ratio is currently at 49.00.
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
Theravance Biopharma (TBPH) has experienced a significant 30.6% decline over the past four weeks, placing it in oversold territory according to its Relative Strength Index (RSI) of 21.54. This technical indicator, combined with a strong consensus among Wall Street analysts for improved earnings and a Zacks Rank #2 (Buy), suggests a potential turnaround for the stock, as selling pressure may be exhausting and estimates for EPS have increased dramatically.
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Theravance Biopharma (NASDAQ:TBPH) has received a consensus "Moderate Buy" rating from seven analysts, with an average 1-year price target of $22.60. Recent analyst activity shows mixed signals, including some downgrades and price target cuts, while HC Wainwright raised its target to $27. Institutional investors hold a significant 99.10% of the stock, with several major firms increasing their positions.
Oppenheimer Downgrades Theravance Biopharma (TBPH) to Perform, March 05 2026
Oppenheimer downgraded Theravance Biopharma (TBPH) from Outperform to Perform on March 5, 2026, citing negative Phase 3 trial results. This downgrade led to a slight intraday price drop of -0.51% and signals increased risk for investors. While Oppenheimer did not provide a new price target, Meyka AI still rates TBPH with an "A" grade, suggesting caution and close monitoring of clinical catalysts.
Theravance Biopharma (TBPH) Downgraded by Oppenheimer to Perform
Oppenheimer has downgraded Theravance Biopharma (TBPH) to 'Perform' from 'Outperform', with no changes to its price target. This follows several recent downgrades and price target reductions from other analyst firms, signaling a shifting sentiment despite the average analyst target still implying a significant upside. Theravance Biopharma focuses on organ-selective medicines, particularly for respiratory diseases.
Theravance Biopharma (NASDAQ:TBPH) Downgraded to "Market Perform" Rating by Oppenheimer
Oppenheimer downgraded Theravance Biopharma (NASDAQ:TBPH) from an "outperform" to a "market perform" rating. Despite this, the biopharmaceutical company maintains a "Moderate Buy" average rating from analysts with a consensus target price of $22.60. Theravance Biopharma focuses on developing and commercializing innovative medicines, with its lead product being YUPELRI®.
